Published Date: 17 Feb 2023
Antibiotic use linked to SJ syndrome and toxic epidermal necrosis, sulfonamides are worst culprits in new study...
Read Full NewsMarlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.
In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.
A post hoc analysis linked more purulent patient-reported sputum to higher neutrophil elastase activity and greater bronchiectasis disease activity.
Sphingolipid Profiles May Distinguish IPF from Fibrotic HP
CHEST 2026: Day 1 Recap — 5 Headlines to Know
PAH Combination Therapy and Escalation: Clinical Forum Perspectives
APP Experts Discuss Earlier Biologic Use in Asthma and COPD
1.
SCOTUS Grapples With Multibillion-Dollar Lawsuits Over Roundup Cancer Claims
2.
Benign or Malignant? No Way to Tell Radiologically
3.
Access to GLP-1 medications associated with a lower risk of colorectal cancer in people with type 2 diabetes: JAMA.
4.
FDA Approves Iberdomide Combo for Multiple Myeloma
5.
The response of bipolar patients to lithium may be predicted by ancestry.
1.
Emerging Therapies Using Immune-Engineered Cancer Eradication Platforms
2.
Digital Oncology Navigation Systems for Coordinated Multidisciplinary Cancer Care
3.
Fatigue, Vitality, and Quality of Life in Hematologic Disorders
4.
Engineered Red Blood Cell Therapeutics: Emerging Applications
5.
Beyond the Brain Fog: The Complex Neurological Challenges and Therapeutic Advances
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
2.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
3.
Case-Based Learning: Oncology
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation